Literature DB >> 16567792

Treatment of local recurrences of giant cell tumour in long bones after curettage and cementing. A Scandinavian Sarcoma Group study.

F Vult von Steyern1, H C F Bauer, C Trovik, A Kivioja, P Bergh, P Holmberg Jörgensen, G Follerås, A Rydholm.   

Abstract

We retrospectively studied local recurrence of giant cell tumour in long bones following treatment with curettage and cementing in 137 patients. The median follow-up time was 60 months (3 to 166). A total of 19 patients (14%) had at least one local recurrence, the first was diagnosed at a median of 17 months (3 to 29) after treatment of the primary tumour. There were 13 patients with a total of 15 local recurrences who were successfully treated by further curettage and cementing. Two patients with a second local recurrence were consequently treated twice. At the last follow-up, at a median of 53 months (3 to 128) after the most recent operation, all patients were free from disease and had good function. We concluded that local recurrence of giant cell tumour after curettage and cementing in long bones can generally be successfully treated with further curettage and cementing, with only a minor risk of increased morbidity. This suggests that more extensive surgery for the primary tumour in an attempt to obtain wide margins is not the method of choice, since it leaves the patient with higher morbidity with no significant gain with respect to cure of the disease.

Entities:  

Mesh:

Year:  2006        PMID: 16567792     DOI: 10.1302/0301-620X.88B4.17407

Source DB:  PubMed          Journal:  J Bone Joint Surg Br        ISSN: 0301-620X


  39 in total

1.  Similar local control between phenol- and ethanol-treated giant cell tumors of bone.

Authors:  Wei-Hsin Lin; Tsung-Yu Lan; Chih-Yu Chen; Karl Wu; Rong-Sen Yang
Journal:  Clin Orthop Relat Res       Date:  2011-07-06       Impact factor: 4.176

2.  Surgical technique: Unicondylar osteoallograft prosthesis composite in tumor limb salvage surgery.

Authors:  Markus Nottrott; Jendrik Hardes; Georg Gosheger; Arne Streitbürger
Journal:  Clin Orthop Relat Res       Date:  2013-04-04       Impact factor: 4.176

3.  Reply to letter to the editor: Surgical technique: Unicondylar osteoallograft prosthesis composite in tumor limb salvage surgery.

Authors:  Hongbin Fan; Zheng Guo; Zhen Wang; Jing Li; Xiangdong Li
Journal:  Clin Orthop Relat Res       Date:  2013-04-04       Impact factor: 4.176

4.  In-depth analysis of local recurrence of giant cell tumour of bone with soft tissue extension after intralesional curettage.

Authors:  Liang Chen; Xiao-Yi Ding; Chengs-Sheng Wang; Ming-Jue Si; Lian-Jun Du; Wei-Bin Zhang; Yong Lu
Journal:  Radiol Med       Date:  2014-03-07       Impact factor: 3.469

Review 5.  Giant cell tumour of bone: a new evaluating system is necessary.

Authors:  Han Wang; Ningjun Wan; Yongcheng Hu
Journal:  Int Orthop       Date:  2012-10-05       Impact factor: 3.075

6.  Conservative treatment of Campanacci grade III proximal humerus giant cell tumors.

Authors:  Richard D Lackman; Eileen A Crawford; Joseph J King; Christian M Ogilvie
Journal:  Clin Orthop Relat Res       Date:  2008-11-06       Impact factor: 4.176

7.  Treatment of giant cell tumor of bone: Current concepts.

Authors:  Ajay Puri; Manish Agarwal
Journal:  Indian J Orthop       Date:  2007-04       Impact factor: 1.251

8.  A case of recurrent giant cell tumor of bone with malignant transformation and benign pulmonary metastases.

Authors:  Ira J Miller; Alan Blank; Suellen M Yin; Allison McNickle; Robert Gray; Steven Gitelis
Journal:  Diagn Pathol       Date:  2010-09-22       Impact factor: 2.644

Review 9.  The impact of curettage technique on local control in giant cell tumour of bone.

Authors:  Gennady N Machak; Andrey I Snetkov
Journal:  Int Orthop       Date:  2020-10-22       Impact factor: 3.075

10.  Bone defects following curettage do not necessarily need augmentation.

Authors:  Martti Hirn; Uday de Silva; Sujith Sidharthan; Robert J Grimer; Adesegun Abudu; Roger M Tillman; Simon R Carter
Journal:  Acta Orthop       Date:  2009-02       Impact factor: 3.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.